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Abstract Continuous dopaminergic treatment is consid-
ered to prevent or delay the occurrence of dyskinesia
in patients with Parkinson’s disease (PD). Rotigotine is a
non-ergolinic D3 [ D2 [ D1 dopamine-receptor agonist
for the treatment of PD using a transdermal delivery system
providing stable plasma levels. We aimed to investigate
the differential influence on gene expression of pulsatile
L-DOPA or rotigotine versus a continuous rotigotine
treatment. The gene expression profile within the nigro-
striatal system of unilateral 6-hydroxydopamine-lesioned
rats was assessed in order to differentiate potential changes
in gene expression following the various treatment using
Affymetrix microarrays and quantitative RT-PCR. The
expression of 15 genes in the substantia nigra and of 11 genes
in the striatum was altered under pulsatile treatments inducing
dyskinetic motor response, but was unchanged under contin-
uous rotigotine treatment that did not cause dyskinetic motor
response. The route of administration of a dopaminergic drug
is important for the induction or prevention of motor abnor-
malities and adaptive gene expressions. The decline of
neurotrophin-3 expression under pulsatile administration was
considered of particular importance.
Keywords Continuous  Dyskinesia  Gene chip  Gene
expression  6-Hydroxydopamine  L-DOPA  Microarray 
Parkinson’s disease  Pulsatile  Quantitative RT-PCR 
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Introduction
The mainstay of treatment in Parkinson’s disease (PD)
has been palliative treatment for dopamine deficiency
with L-DOPA (L-3,4-dihydroxyphenylalanine, levodopa)
or dopamine agonists. However, after few years of treat-
ment, the occurrence of motor complications limits the
usefulness of especially L-DOPA (Jankovic 2005; Jenner
2008). It has been proposed that pharmacokinetic factors
such as pulsatile drug administration and pharmacody-
namic alterations in the brain of PD patients are causative
factors (Nutt 2007; Cenci 2007). Recent studies suggest
that pulsatile delivery of L-DOPA results in changes in gene
and protein expression and in subsequent alterations of the
firing patterns of neurons (Chase 2004; Valastro et al. 2007,
Sgambato-Faure et al. 2005).
Rotigotine, is a non-ergolinic D3 [ D2 [ D1 dopamine-
receptor agonist for once daily treatment of PD formulated
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in a patch providing a sustained drug release over 24 h
(Baldwin and Keating 2007; Giladi et al. 2007; Steiger
2008). In the MPTP-induced PD in mice, continuous
rotigotine administration reduced dyskinesia in comparison
to pulsatile treatment with rotigotine or L-DOPA (Stockwell
et al. 2010). Stable plasma levels are thought to maintain
continuous dopaminergic stimulation and to prevent
induction of dyskinesia.
In the present study, the unilaterally 6-hydroxydopamine
(6-OHDA) lesioned rat (Jenner 2008) was used as a model
of PD to investigate the relationship between adaptive gene
expression changes and the occurrence of motor compli-
cations under different treatment regimen. Rats sustaining
such lesions exhibit robust contraversive turning following
dopaminergic treatment due to hypersensitization of the
dopamine receptors ipsilateral to the lesion (Jenner 2008)
and abnormal involuntary movements (AIMs, Cenci 2002;
Cenci et al. 1998). Recently, we reported that the contin-
uous in contrast to the pulsatile administration of rotigotine
did not induce sensitization nor AIMs, suggesting that
continuous stimulation of dopaminergic receptors by
rotigotine has no or a low propensity to induce dyskinesia
in this experimental model (Schmidt et al. 2008). Here,
transcript profiling via microarray was used to examine
the expression changes of over 1,200 sequences in the
substantia nigra (SN) and striatum under continuous or
pulsatile treatment conditions. We focused on the genes of
the dopaminergic, serotonergic and glutamatergic system
that are hypothesized to be involved in the pathogenesis of
L-DOPA-induced dyskinesia and aimed at testing the
hypothesis that the pulsatile administration of rotigotine or
L-DOPA would lead to a differential gene expression
compared to a continuous administration of rotigotine.
Materials and methods
Animal experiments
Animal experiments were carried out at the Department of
Neuropharmacology (University of Tu¨bingen). All proce-
dures were done in accordance with the ethical principles
and to the requirements of the German laws on animal
experimentation. The study protocol was approved by the
local ethical committee and the local legal authority.
6-OHDA lesions and behavioral testing
The induction of unilateral lesions and of behavioral testing
is described elsewhere (Schmidt et al. 2008). In short, male
Sprague–Dawley rats (BW 220–250 g, Charles River,
Germany) housed under standard conditions (RT 22.5C,
relative humidity 55%; 12/12-h light/dark cycle with access
to water ad libitum but limited access to food (15 g per animal
and day). Under anesthesia with pentobarbital-sodium
(Narcoren, Merial Hallbergmoos, Germany, 64 mg/kg, i.p.)
and desipramine hydrochloride (Sigma Taufkirchen,
Germany, 20 mg/kg, i.p.), 6-OHDA hydrobromide (12 lg
(free base dissolved in 1 lL ascorbic acid 0.01%, Sigma
Taufkirchen, Germany) was infused into the left medial
forebrain bundle at a rate of 0.25 lL/min [coordinates in
respect to bregma: A = 4.0 mm, L = 1.6 mm, and H =
8.8 mm (Paxinos and Watson 1986)]. Retrograde degenera-
tion of the dopaminergic cells developed over 29 days. Only
those rats demonstrating a spontaneous ipsiversive rotation in
a novel environment were included in the test which has been
demonstrated as a clear indicator for an effective lesioning
(Metz et al. 2005). A challenge test with a standard dose of
L-DOPA or apomorphine had to be omitted, as even a single
administration of either compound may have caused priming
for sensitization or AIMs (Morelli et al. 1991).
Animal treatment
The rats were randomly divided in four experimental
groups and were treated for 10 days (day 30–39 after
surgery) followed by a 5 day drug-free period and a
re-testing for confirmation of established sensitization and
dyskinesia: group 1 [(GI, control) saline; group 2 (GII)
10 mg/kg L-DOPA and 15 mg/kg benserazide; group 3
(GIII) continuous rotigotine (1 mg/kg slow release
formulation prepared as oily suspension of 0.1% rotigotine
(SCHWARZ PHARMA); group 4 (GIV) pulsatile rotigo-
tine (1 mg/kg, dissolved as 1.0 mg/mL in 1:15 DMSO/
saline (SCHWARZ PHARMA)]. L-DOPA and rotigotine
doses were selected based on consistent effects as observed
in previous studies (Alam et al. 2004) and providing
plasma levels similar to those achieved in humans (Elshoff
et al. 2006).
Sample and array processing
Brain tissue preparation
On day 18 after onset of treatment (day 47 after surgery)
the animals were deeply anesthetized with halothane and
intubated. After 20 min, the brains were frozen in situ by
liquid nitrogen poured into a skin funnel. The frozen brains
were chiseled out and the striatum and SN region from
the damaged side (left side) were dissected (-20C in a
cryostate chamber) and stored at -80C.
Total RNA extraction
Total RNA was isolated from the dissected tissue and
separately for each animal using RNeasy Midi Kit (Qiagen,
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Hilden, Germany), following the procedure described by
the reagent’s manufacturer. For Gene Chip expression
probe array hybridization, total RNA was pre-treated with
DNase I as previously described (Gru¨nblatt et al. 2004a, b).
Additional quality test of the RNA, before going to the
GeneChip arrays, was performed using the GeneChip
Test3 Array (Affymetrix, Santa Clara, USA).
cRNA labeling and array hybridization
Rat Neurobiology GeneChip array (Affymetrix, Santa
Clara, USA), consisting of approximately [1,200 genes
each (of known genes and ESTs) was employed. The
RNA samples from the different animals were pooled for
each treatment group and brain region (per pool ten
samples) resulting with eight groups (four treatments, two
regions). Pooling was performed in triplicates per treat-
ment group, and per brain region. Labeled cRNA was
prepared from the different pools of total RNA using
GeneChip Two-Cycle Target Labeling and Control
Reagents. This technique utilized biotin-labeled and
fragmented complementary RNA that was hybridized to
the chip. Preparation of the cRNA and defragmentation
were conducted according to the manufacturer’s protocol
(Affymetrix, Santa Clara, USA). The hybridization and
scanning of the probe arrays were performed as previ-
ously described (Gru¨nblatt et al. 2004a, b; Jacob et al.
2007).
Data analysis and criteria for gene selection
Results are averaged from triplicate independent array
hybridization experiments. The data analysis was
performed using Vector XpressionTM 3.0 Microarray Data
Analysis Software (Invitrogen GmbH, Karlsruhe,
Germany). Data of each array was normalized by dividing
the median of its gene expression value. Data were then
filtered based on the following criteria: (1) Hybridization
was robust and therefore the gene’s expression was
‘‘present’’ in at least one of the sample groups according to
Affymetrix criteria, (2) hybridization levels were rated
as ‘‘changed’’ according to MAS5 criteria, (3) the fold
change ratio between medication group and controls
was C1.5 (log2 [ 0.58; significant up-regulation) or B0.67
(log2 \ -0.58, significant down-regulation). Wilcoxon test
was conducted for significance of the triplicate independent
hybridization experiments.
Quantitative RT-PCR
Total RNA (1 lg for striatum, 100 ng for SN) from each
sample was reverse transcribed with random hexamer and
oligo-dT primers using iScriptTM cDNA Synthesis Kit
(BioRad Laboratories, Hercules, CA, USA, Cat. No. 170-
8890). The genes were normalized to the house-keeping
genes: b-actin, ribosomal 18S, a-tubulin and glycer-
aldehyde-3-phosphate dehydrogenase (GAPDH) (Table 1).
The house-keeping genes were tested for their stability
using the GeNorm program (http://medgen.ugent.be/*
jvdesomp/genorm/) (Vandesompele et al. 2002). After
analysis for the most stable house-keeping genes, a
normalization factor was calculated according to the pro-
gram GeNorm. Absence of DNA contamination was veri-
fied by amplifying the house-keeping gene, ribosomal 18S,
and run on gel to observe no product. Minus RT samples
were tested simultaneously with experimental samples by
quantitative RT-PCR (Q-RT-PCR) in order to see whether
the reaction did not yield any amplification below 35 cycles
using the PCR protocol. Eight genes (Table 1) were
assessed for their gene expression profiles in the SN and
striatum from the left side. Q-RT-PCR was performed on
the iCycler iQ system (BioRad Co., Hercules, CA, USA) as
described previously (Gru¨nblatt et al. 2004a). QuantiTect
SYBR Green PCR Kit was used for the analysis of the
various genes (Qiagen Inc., Valencia, CA, USA). All PCR
reactions were run in triplicate and for each sample indi-
vidually. A melting point analysis was conducted to further
confirm analysis of one product detection on the Q-RT-
PCR analysis. Standard curves for each amplification
product were generated from tenfold dilution of pooled
cDNA amplicons to determine primer efficiency and
quantization. Amplicons were harvested from the first
RT-PCR test of each gene and their extraction from aga-
rose gel electrophoresis using the MiniElute Gel extraction
kit (Qiagen). Data was analyzed with Microsoft Excel 2000
to generate raw expression values.
Data analysis
Results reported here are averaged from triplicate inde-
pendent Q-RT-PCR experiments for the individual rat
brain region. The amplified transcripts were quantified
using the comparative threshold cycle (CT) method. For the
accurate normalization of Q-RT-PCR data the geometric
averaging of multiple internal control genes (the most
stable house-keeping genes) was used according to the
program GeNorm (Vandesompele et al. 2002). Kruskal–
Wallis One Way Analysis of Variance (ANOVA) on Ranks
and pair wise multiple comparisons versus control group
(Dunn’s Method) was conducted for significance of the
triplicate independent experiments. Analysis was con-
ducted on the PC program Sigma Plot 9.0 (Systat Software
GmbH, Erkrath, Germany). Significant differences were
defined as those with a P value \0.05.
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Results
Using stringent criteria for the selection of meaningful
candidate genes, 1,150 out of 1,322 transcripts (87%)
assessed reached Affymetrix criteria ‘‘present’’ and
‘‘changed’’ in the SN, while 829 out of 1,322 transcripts
(63%) assessed reached Affymetrix criteria ‘‘present’’ and
‘‘changed’’ in the striatum. At a probability level below
0.05 (P \ 0.05), 8.1 and 5.1% of these mRNAs were
expressed at altered levels in the SN and striatum,
respectively, of unilateral 6-OHDA-lesioned rats that
developed dyskinetic motor response. The expression of 68
mRNAs was up- and that of 69 mRNAs was down-regu-
lated within the SN whereas the expression of 33 mRNAs
was up- and 35 mRNAs was down-regulated within the
striatum.
Differentially expressed genes associated with the
dopaminergic, serotoninergic and glutamatergic neuro-
transmission are summarized in Tables 2 and 3. Dysregu-
lation of these neurotransmitter systems is potentially
involved in the pathophysiology of dyskinesia (Jenner
2008; Brotchie 2005).
As depicted in Table 2, only 20 genes were changed in a
similar way in the SN of unilateral 6-OHDA-lesioned rats
that developed dyskinetic motor response following
pulsatile L-DOPA- and rotigotine treatment. The transcripts
of orotidine-50-phosphate decarboxylase, retinal guanylate
cyclase 2F, member 6 of the tumor necrosis factor super-
family, BH3 interacting domain, rat tumor necrosis factor,
alpha type 2 of glutathione-S-transferase, glial high affinity
glutamate transporter, metabotropic 2 and 5 glutamate
receptor, ionotropic kainate 2 glutamate receptor, serotonin
5B and 1A receptor were up-regulated whereas guanylyl
cyclase, BCL2-like 11 and the serotonin transporter were
down-regulated. Interestingly, all these changes were either
not changed due to the lesion and treatment or were
normalized in those rats which received the continuous
treatment with rotigotine.
In the striatum (Table 3), only 19 genes were changed in
a similar way. The transcripts of insulin-like growth factor
binding protein 5 (Accession no. rc_AI029920), insulin-
like growth factor 2, fibroblast growth factor 5, metabo-
tropic 2 glutamate receptor, serotonin 2A and 5A receptor
and the serotonin transporter were up-regulated whereas
Table 1 QuantiTect primer assays conditions for real-time quantitative RT-PCR
Gene Accession
no.
Gene
symbol
QuantiTect
primer assay
Detection
method
Product
size (bp)
Cycle
no.
Reaction
efficiency (%)
Melting
point (C)
Ribosomal 18s M11188 Rnr1 Cat nr: QT
00199374
SYBR 103 40 92.3 88
Beta-actin NM_031144 Actx Cat nr: QT
00193473
SYBR 145 37 98.1 85.5
Alpha-tubulin NM_022298 Tuba1 Cat nr: QT
00195846
SYBR 85 40 100 85.5
Glyceraldehyde-3-phosphate dehydrogenase NM_017008 Gapd Cat nr: QT
00199633
SYBR 83 35 100 84.5
Neurotrophin 3 NM_031073 Ntf3 Cat nr: QT
00184373
SYBR 106 45 99 79
Insulin-like growth factor 2 NM_031511 Igf2 Cat nr: QT
00195594
SYBR 96 40 100 86,5
Tumor necrosis factor superfamily, member 2 NM_012675 Tnf Cat nr: QT
00178717
SYBR 75 45 95.2 80.5
Glutamate receptor, metabotropic 2 XM_343470 Grm2 Cat nr: QT
00373030
SYBR 73 45 83.3 78.5
Solute carrier family 1; glial high
affinity glutamate transporter; member 2
NM_017215 Slc1a2 Cat nr: QT
00181090
SYBR 91 40 93.2 81
Solute carrier family 6 neurotransmitter
transporter, serotonin, member 4
NM_013034 Slc6a4 Cat nr: QT
00176827
SYBR 83 40 100 78
5-hydroxtryptamine receptor 1A NM_012585 Htr1a Cat nr: QT
00412643
SYBR 117 45 96.6 84
5-hydroxtryptamine receptor 2A NM_017254 Htr2a Cat nr: QT
00382893
SYBR 125 40 98.4 82
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neurotrophin-3, insulin-like growth factor binding protein 5
(Accession no. M62781), member 2 of the tumor necrosis
factor superfamily and interleukin 10 were down-regulated.
Again, all these changes were normalized in rats with
continuous treatment of rotigotine.
The microarray and the Q-RT-PCR analysis are sum-
marized in Table 4. Among the eight genes tested in the
SN and striatum, the patterns of gene expression deter-
mined in the microarray analysis were not confirmed in all
treatment groups by Q-RT-PCR analysis. We found for all
genes examined a similar pattern of gene expression in the
group treated continuously with rotigotine, whereas a dif-
ferent expression pattern was observed under pulsatile
treatment of L-DOPA (for all genes) and rotigotine
(six of eight genes). Similar results were found for the
neurotrophin-3 and the metabotropic 2 glutamate receptor
gene in the group treated with pulsatile rotigotine. Other
genes such as the insulin-like growth factor 2, the metab-
otropic 2 glutamate receptor, the solute carrier family 6
neurotransmitter transporter (serotonin, member 4), and the
5-hydroxytryptamine receptor 2A showed the same
tendency in the Q-RT-PCR analysis as compared to the
gene chip analysis but did not reach significance (Table 4).
Only the changes observed regarding neurotrophin-3
reached statistical significance.
Regarding the SN, the increase of both the solute carrier
family 1 glial high affinity glutamate transporter (member
2) and the 5-hydroxytryptamine receptor 1A genes showed
the same tendency as observed by gene chip analysis but
did not reach significance (Table 4).
Table 2 Genes in the substantia nigra of unilateral 6-hydroxydopamine-lesioned rats that developed dyskinetic motor response following L-
DOPA and pulsatile rotigotine treatment and are similarly changed
Gene name and functional group Accession no. Log2(GII/GI) Log2(GIII/GI) Log2(GIV/GI)
Genes involved in enzyme metabolism
Orotidine-50-phosphate decarboxylase AFFX-YEL0-
21w/URA3
0.518 0.368 0.518
Guanylyl cyclase (GC-E) L36029 -1.584 0.120 -0.891
Guanylate cyclase 2F, retinal L36030 0.961 -0.071 0.915
Genes involved in apoptosis
Tumor necrosis factor receptor superfamily, member 6 AFFX-MurFAS 0.853 0.569 1.380
BH3 interacting (with BCL2 family) domain, apoptosis agonist D83697 1.111 0.435 0.586
BCL2-like 11 (apoptosis facilitator) AF065432 -1.143 0.312 -1.459
Rat tumor necrosis factor receptor (TNF receptor) mRNA,
complete cds
M63122 0.932 0.360 0.969
Genes involved in the metabolism of reactive oxygen species
Glutathione-S-transferase, alpha type2 rc_AI235747 0.627 0.096 1.020
Genes involved in neurotransmission
Dopamine receptor 1A S46131mRNA 0.248 1.038 0.537
Solute carrier family 1 (glial high affinity glutamate transporter),
member 2
rc_AI044517 1.742 0.510 1.801
Glutamate receptor, metabotropic 5 D10891 1.485 0.516 0.871
Glutamate receptor, metabotropic 4 M90518 -0.102 0.910 -0.124
Glutamate receptor, metabotropic 2 M92075 2.843 0.110 1.388
Glutamate receptor, ionotropic, kainate 2 Z11548 1.786 0.126 1.393
Glutamate receptor, ionotropic, N-methyl-D-aspartate 1 S39221 0.394 0.781 0.341
Glutamate receptor, ionotropic, N-methyl-D-aspartate 1 L08228exon#22 0.388 0.584 0.172
Glutamate receptor, ionotropic, N-methyl-D-aspartate 2A AF001423 0.332 0.686 0.535
Solute carrier family 6 (neurotransmitter transporter, serotonin),
member 4
X63995 -0.909 0.168 -1.703
5-hydroxytryptamine (serotonin) receptor 5B L10073 1.162 0.136 0.548
5-hydroxytryptamine (serotonin) receptor 1A J05276cds 0.628 -0.462 0.738
The ratio (treatment/control) was set as C1.5 (log2 [ 0.58; significant up-regulation) or B0.67 (log2 \ -0.58, significant down-regulation). All
rations are as log2. Significant changes are in bold
GI unilateral 6-hydroxydopamine (6-OHDA)-lesioned rats treated with vehicle, control group, GII 6-OHDA-lesioned rats treated chronically
with L-DOPA, GIII 6-OHDA-lesioned rats with chronic continuous rotigotine treatment, GIV 6-OHDA-lesioned rats with chronic pulsatile
rotigotine treatment
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Discussion
The present study used microarray analysis to profile nigral
and striatal gene expression changes in unilateral 6-OHDA-
lesioned rats following pulsatile and continuous treatment
with dopamimetic drugs. In agreement with the literature
(Cenci 2002) we found that repetitive, pulsatile dopami-
nergic treatment (L-DOPA, rotigotine) caused a dyskinetic
motor response (sensitization of rotation, AIMs). In con-
trast, continuous administration of rotigotine did not induce
this dyskinetic response (Schmidt et al. 2008). Pulsatility is
thought to be an important pharmacokinetic determinant
for the induction of dyskinesia because normal striatal
dopamine-receptor stimulation is thought to be continu-
ous (Jenner 2008). Thus, the changes in gene expression
occurring under pulsatile treatment could be specific indi-
cators for adaptive changes during generation of
dyskinesia.
The fact, that pulsatile administration of both L-DOPA
and rotigotine caused a dyskinetic motor response whereas
continuous administration of rotigotine did not, was used as
selection criteria to focus on those genes related to dyski-
nesia and those that did not change during continuous
administration. Besides receptors of the serotoninergic
system (for SN see Table 2; for striatum see Table 3) and
of the glutamatergic system, some genes in relation to
structural adaptations were found to be changed as well.
Some of the transcripts were differentially regulated in the
SN and the striatum. At present, the meaning of these
observations is not understood. However, the fact that some
gene changes related to the pulsatile administration of
rotigotine are unchanged under continuous administration
could indicate that, its continuous administration could
prevent plasticity changes in the nigro-striatal system.
These genes, therefore, are interesting candidates for fur-
ther investigations on the mechanisms inducing dyskinesia
Table 3 Genes in the striatum of unilateral 6-hydroxydopamine-lesioned rats that developed dyskinetic motor response following L-DOPA and
pulsatile rotigotine treatment and are similarly changed
Gene name and functional group Accession no. Log2(GII/GI) Log2(GIII/GI) Log2(GIV/GI)
Genes involved in growth factor metabolism
Neurotrophin 3 E03082cds -2.614 -0.174 -0.740
Insulin-like growth factor binding protein 5 rc_AI029920 0.814 -0.115 0.864
Insulin-like growth factor binding protein 5 M62781 -1.178 -0.435 -1.238
Insulin-like growth factor 2 X16703 1.534 -0.147 3.123
Fibroblast growth factor 5 D64085 0.722 -0.336 0.637
Genes involved in apoptosis
Tumor necrosis factor superfamily, member 2 E02468cds -0.983 -0.046 -0.971
Genes involved in inflammation
Interleukin 10 AFFX-MurIL10 -1.150 -0.035 -1.233
Genes involved in neurotransmission
Trytophan hydroxylase X53501cds -0.518 -0.583 0.229
Glutamate receptor, metabotropic 2 M92075 0.619 0.360 0.525
Solute carrier family 1 (high affinity aspartate/glutamate
transporter), member 6
U89608 0.240 0.619 -0.201
Glutamate receptor, ionotropic, delta 2 U08256 -0.141 -0.690 -0.500
Glutamate receptor, ionotropic, kainate 4 X59996mRNA -0.049 -0.876 0.352
Glutamate receptor, ionotropic, N-methyl-D-aspartate 2A D13211 -0.138 -0.858 0.214
5-Hydroxytryptamine (seretonin) receptor 7 L22558 -0.428 -0.590 -0.365
5-hydroxytryptamine (serotonin) receptor 5A L10072 1.207 0.167 1.294
5-hydroxytryptamine (serotonin) receptor 2A M64867 1.247 0.113 0.702
5-Hydroxytryptamine (seretonin) receptor 2A L31546cds 0.065 -0.699 -0.348
5-Hydroxytryptamine (seretonin) receptor 1A J05276cds 0.128 -1.029 0.175
Solute carrier family 6 (neurotransmitter transporter, serotonin),4 X63995 0.991 0.373 1.785
The ratio (treatment/control) was set as C1.5 (log2 [ 0.58; significant up-regulation) or B0.67 (log2 \ -0.58, significant down-regulation). All
rations are as log2. Significant changes are in bold
GI unilateral 6-hydroxydopamine (6-OHDA)-lesioned rats treated with vehicle, control group, GII 6-OHDA-lesioned rats treated chronically
with L-DOPA, GIII 6-OHDA-lesioned rats with chronic continuous rotigotine treatment, GIV 6-OHDA-lesioned rats with chronic pulsatile
rotigotine treatment
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following pulsatile but not continuous dopaminergic
treatment.
Studies on post-mortem tissues from PD patients and
from animals that developed dyskinetic motor responses
indicate that the neurotransmitter and neuromodulator
systems of the direct and the indirect pathways are altered
during the expression of dyskinesia (Jenner 2008) includ-
ing especially the D1 receptor (Guigoni et al. 2007; Kon-
radi et al. 2004). However, we did not find an up-regulation
of the D1 receptor gene in pulsatile-treated rats in the
striatum (Table 2) but a down-regulation of the gene for
the dopamine 1A receptor in the SN in pulsatile-treated rats
whereas an up-regulation was observed under continuous
rotigotine treatment (Table 2). In contrast to the supposed
role of dopamine or glutamate receptors, our observations
rather point to a more pronounced role of the serotonin-
ergic systems for dyskinetic motor response which is in
contrast to the findings of Konradi et al. (2004). The
changes in the expression of mRNA related to the seroto-
nergic system, however, are in line with a serotonergic
hyperinnervation of the lesioned side (Maeda et al. 2005).
We performed Q-RT-PCR only on a representative
subset of genes that were found altered in the microarray
analysis. Among the eight genes tested, the expressions
patterns found in the microarray analysis showed the same
trend in the Q-RT-PCR analysis; however, they did not
reach statistical significance with the exception of the NT3
gene. The large variability observed in the individual
samples might be the cause. However, all genes in the
group treated continuously with rotigotine and investigated
by the Q-RT-PCR were confirmed to remain unchanged.
The differences in gene expression as observed by the two
methods may have resulted from multiple causes, espe-
cially technical differences: in the microarrays, pooled
RNA from different animals was used for each array, while
in the Q-RT-PCR analysis we analyzed the profiles for
each rat separately. The different sequences of the genes
used in the different analyses may also have caused an
enhanced variation.
Alteration of the neurotrophin-3 mRNA was confirmed
in both assays. The neurotrophin-3 mRNA expression
within the striatum was decreased under pulsatile treatment
with either drug, whereas under continuous rotigotine
treatment the expression pattern remained unchanged.
Neurotrophins are well known to be involved in growth
and survival of neurons in the brain (Apfel 1999). In ani-
mals, haploinsufficiencies of the neurotrophin receptors
trkB and/or trkC were reported to promote a PD-like
phenotype (von Bohlen und Halbach et al. 2005). Recently,
apoptosis induced-6-OHDA in PC12 cells was shown to be
inhibited via pretreatment with neurotrophin-3 (Li et al.
2008). Li et al. (2008) could show that neurotrophin-3
prevented 6-OHDA-induced apoptosis in PC12 cells via
activation of PI3-kinase/Akt pathway. Concomitantly, Gu
et al. (2009) could demonstrate that transplantation of rat
neural stem cells that express neurotrophin-3 endogenously
into 6-OHDA-treated rats has higher and better behavioral
improvements, regeneration of tyrosine hydroxylase posi-
tive cells number and migration distance compared to
normal stem cells. This indicates a potentially important
role of neurotrophin-3 also in development of dyskinesia.
In conclusion, our observations indicate that continuous
and pulsatile administration of dopaminergic compounds
may lead to a differential adaptation in gene expression
pattern and thus point to the role of several genes in the
generation of dyskinetic motor response. As these are the
first observations for a differential regulation of gene
expression with respect to different treatment regimens,
further studies are needed to confirm the results. Never-
theless, the data support the idea that a continuous
administration of dopaminergic drugs seems to be advan-
tageous as the adaptive changes as well as the motor
complications may be avoided.
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